Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy
Adrienne Luoma, Shengbao Suo, Yifan Wang, et al.
Cell (2022) Vol. 185, Iss. 16, pp. 2918-2935.e29
Open Access | Times Cited: 235

Showing 26-50 of 235 citing articles:

HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Qinqin Jiang, David A. Braun, Karl R. Clauser, et al.
Cell (2025)
Open Access | Times Cited: 2
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Housaiyin Li, Dan P. Zandberg, Aditi Kulkarni, et al.
Cancer Cell (2025)
Open Access | Times Cited: 2
The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors
Anna Tosi, Beatrice Parisatto, Anna Menegaldo, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 44
Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens
Yiping Wang, Joy Linyue Fan, Johannes C. Melms, et al.
Nature Genetics (2023) Vol. 55, Iss. 1, pp. 19-25
Open Access | Times Cited: 37
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
Fan Yang, Chloe Shay, Marin Abousaud, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 36
Bodywide ecological interventions on cancer
Guido Kroemer, Jennifer L. McQuade, Miriam Mérad, et al.
Nature Medicine (2023) Vol. 29, Iss. 1, pp. 59-74
Closed Access | Times Cited: 35
Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors
In-Young Jung, Estela Noguera-Ortega, Robert L. Bartoszek, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 6, pp. 101053-101053
Open Access | Times Cited: 32
Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer
Cem Sievers, Marco Craveiro, Jay Friedman, et al.
Cancer Cell (2023) Vol. 41, Iss. 5, pp. 887-902.e5
Open Access | Times Cited: 31
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
Rami Yossef, Sri Krishna, Sivasish Sindiri, et al.
Cancer Cell (2023) Vol. 41, Iss. 12, pp. 2154-2165.e5
Open Access | Times Cited: 31
Spatial and Single-Cell Transcriptomics Reveal a Cancer-Associated Fibroblast Subset in HNSCC That Restricts Infiltration and Antitumor Activity of CD8+ T Cells
Chuwen Li, Haiyan Guo, Peisong Zhai, et al.
Cancer Research (2023) Vol. 84, Iss. 2, pp. 258-275
Open Access | Times Cited: 30
STAPLER: Efficient learning of TCR-peptide specificity prediction from full-length TCR-peptide data
Bjørn P. Y. Kwee, Marius Messemaker, Eric Marcus, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 26
Multimodal single-cell datasets characterize antigen-specific CD8+ T cells across SARS-CoV-2 vaccination and infection
Bingjie Zhang, Rabi Upadhyay, Yuhan Hao, et al.
Nature Immunology (2023) Vol. 24, Iss. 10, pp. 1725-1734
Open Access | Times Cited: 26
The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives
Amy J. Wisdom, Christopher A. Barker, Joe Y. Chang, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 118, Iss. 5, pp. 1404-1421
Closed Access | Times Cited: 13
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates
Jürgen C. Becker, Andreas Stang, David Schrama, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 541-557
Open Access | Times Cited: 13
Exploiting temporal aspects of cancer immunotherapy
Rachael M. Zemek, Valsamo Anagnostou, Inês Pires da Silva, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 7, pp. 480-497
Closed Access | Times Cited: 13
Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma
Thomas H. Pulliam, Saumya Jani, Lichen Jing, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101412-101412
Open Access | Times Cited: 12
New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication
Sha Qin, Bin Xie, Qingyi Wang, et al.
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 12
Merkel cell polyomavirus-specific and CD39+CLA+ CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma
Heeju Ryu, Timothy Bi, Thomas H. Pulliam, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101390-101390
Open Access | Times Cited: 11
The Role of the Microbiome in the Etiopathogenesis of Colon Cancer
Geniver El Tekle, Natalia Andreeva, Wendy S. Garrett
Annual Review of Physiology (2024) Vol. 86, Iss. 1, pp. 453-478
Open Access | Times Cited: 11
Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites
Tara Muijlwijk, Dennis N L M Nijenhuis, Sonja H. Ganzevles, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007573-e007573
Open Access | Times Cited: 10
NaCl enhances CD8+ T cell effector functions in cancer immunotherapy
Caterina Scirgolea, Rosa Sottile, Marco De Luca, et al.
Nature Immunology (2024) Vol. 25, Iss. 10, pp. 1845-1857
Closed Access | Times Cited: 10
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
Zhongchao Li, Jing Liu, Bo Zhang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Association of pretreatment neutrophil-to-lymphocyte ratio with clinical outcomes in cancer immunotherapy: An evidence synthesis from 30 meta-analyses
Haoyu Wang, Ruiyuan Yang, Dan Liu, et al.
International Immunopharmacology (2024) Vol. 132, pp. 111936-111936
Closed Access | Times Cited: 8
The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial
Bo Cheng, Caichen Li, Jianfu Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma
Zheyi Wang, Yue Zhao, Yang Wo, et al.
Cancer Letters (2024) Vol. 593, pp. 216951-216951
Closed Access | Times Cited: 8

Scroll to top